Overview Welcome Letter: Sizing Up the Great Adaptation Healthcare’s resilience attracts both more capital and creative new forms of capital. Healthcare Private Equity Market 2021: The Year in Review The industry roared back after a pandemic-induced lull in 2020. Hot Topics Covid-19 Fallout: Investing to Handle Pandemics Present and Future Healthcare companies are responding to changes wrought by the coronavirus and gearing up to anticipate future outbreaks. Now Playing: The Return of the Healthcare Megadeal More private equity sponsors team up to win bids and spread risk. Growth Equity Blossoms in Emerging Tech-Related Healthcare Firms Incremental capital helps cutting-edge firms scale up operations. Healthcare Private Equity Deal Returns: Look to Revenues and Multiples Margin expansion, currently a minor factor in returns, is bound to become more important. Healthcare Corporate M&A: Rebounding from the Pandemic Record-high valuations are forcing acquirers to get creative. Healthcare Exits: Corporate Buyers Step Up Roll-ups and portfolio expansion underlie many corporate deals. Healthcare Private Equity Outlook: 2022 and Beyond Investors are hunting for value in a time of discontinuity. Regions Healthcare Private Equity in North America: Macro Trends Broaden Investment Opportunities Capital is flowing to innovative technologies and business models across sectors. Healthcare Private Equity in Europe: Funds Take On More Risk in a Hot Market Investors look for companies that can easily scale up across borders. Healthcare Private Equity in Asia-Pacific: A Multiyear Growth Trajectory Large-scale and tech-savvy assets get the lion’s share of investment. Sectors Biopharma: Traditional Pharma Services Lead the Way Big deals roar back, especially in Europe. Providers: Sparks of Innovation in Primary Care, but Labor Tightens The upheavals of Covid-19 spurred providers to adapt and private equity to close a record year. Payers: A Shift from Insurance to Services Payers look to advanced data analytics and member engagement in order to lower costs and improve outcomes. Medtech: The Pandemic Has Expanded Needs and Opportunities Deals flow from provider demand for supply chain resilience, expense management, and support for alternative care. Life Sciences Tools: Diagnostics Deals on the Rise Diagnostics labs and R&D technology firms have attracted more investments from private equity firms. Healthcare IT: Faster, Smarter, Tuned to Value It’s all about streamlining operations or improving outcomes.
